KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Consolidated Net Income (2016 - 2025)

Emergent BioSolutions' Consolidated Net Income history spans 14 years, with the latest figure at -$54.6 million for Q4 2025.

  • For Q4 2025, Consolidated Net Income fell 74.44% year-over-year to -$54.6 million; the TTM value through Dec 2025 reached $52.6 million, up 127.6%, while the annual FY2025 figure was $52.6 million, 127.6% up from the prior year.
  • Consolidated Net Income reached -$54.6 million in Q4 2025 per EBS's latest filing, down from $51.2 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of $177.9 million in Q4 2021 to a low of -$283.1 million in Q2 2024.
  • Average Consolidated Net Income over 5 years is -$44.7 million, with a median of -$32.0 million recorded in 2021.
  • Peak YoY movement for Consolidated Net Income: soared 657.6% in 2021, then crashed 4932.43% in 2023.
  • A 5-year view of Consolidated Net Income shows it stood at $177.9 million in 2021, then plummeted by 137.66% to -$67.0 million in 2022, then increased by 26.12% to -$49.5 million in 2023, then surged by 36.77% to -$31.3 million in 2024, then tumbled by 74.44% to -$54.6 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Consolidated Net Income are -$54.6 million (Q4 2025), $51.2 million (Q3 2025), and -$12.0 million (Q2 2025).